Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Date:11/3/2009

rward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing, including the risk that the FDA may not approve picoplatin for use in the treatment of SCLC; if regulatory approval is received, the market's acceptance of picoplatin in the treatment of SCLC or the occurrence of post-approval problems that may require the withdrawal of picoplatin from the market; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel and enter into strategic collaborations on favorable terms; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended September 30, 2009, which will be filed with the SEC on or about November 6, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.




                           Poniard Pharmaceuticals, Inc.
                  
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
2. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
6. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Poniard Pharmaceuticals Files Shelf Registration
9. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
10. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... the fight against terrorism with the creation of a ... the use of light and special glass fibres. , ... Chemical , the researchers describe a novel optical fibre ... as 6.3 ppm (parts per million). It requires an ... explosives detection has involved looking for metals that encase ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2
... , COPENHAGEN, June 4 ... an inhibitor of HIF-1alpha, jointly developed by,Enzon Pharmaceuticals and ... signs of clinical benefit in previously treated cancer patients ... solid,tumors and lymphoma. The study data, which was presented ...
... June 4 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... , , 8th ... Eastern Time at the New York Palace Hotel in New York City. , ... June 18, 2009 at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel ...
... Austria, June 4 EUCODIS Bioscience, a company,developing ... announced today that it has successfully launched its ... by EUCODIS,Bioscience and can be supplied in a ... antibiotics manufacturers to improve,quality control, to the diagnostics ...
Cached Biology Technology:LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 2LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 3Optimer Pharmaceuticals to Present at June 2009 Investor Conferences 2EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries 2
(Date:7/11/2014)... near the City of Entiat on Tuesday, July 8, ... quickly grew to over 1,000 acres by evening. Three ... under investigation by the Washington Department of Natural Resources. ... resources in developing fire control strategies and tactics. Other ... Department of Natural Resources, (WA DNR), Bureau of Land ...
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Steven Chu announced today the winners of the 2009 E.O. ... supporting the Department of Energy and its missions. The ... citation and $50,000. Winners will be honored at ... made by these researchers to advance the national, economic and ...
... short-term, seasonal exposure to pesticides in rivers and basins ... populations. In addition to the widespread deterioration of salmon ... pesticides may further inhibit the recovery of threatened or ... to restore Pacific salmon habitats in an effort to ...
... , , SUNNYVALE, Calif., Dec. 1 GestureTek ... 3.0 - a turnkey, portable, plug and play interactive ... promotions. GestureTek is the inventor and holder of dozens ... display, presentation and entertainment systems. , Guaranteed for quality, ...
Cached Biology News:Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Request Info...
Biology Products: